Tactile Systems Technology (NASDAQ:TCMD) Stock Crosses Above 200 Day Moving Average on Analyst Downgrade

Key Points

• TCMD shares rose above their 200-day moving average, reaching $28.71 during trading and later trading at $27.18. Wall Street Zen upgraded the stock from Buy to Strong Buy.
• Analyst sentiment is broadly positive: four analysts rate the shares Buy and two Hold, producing a Moderate Buy consensus and an average price target of $36.80. BTIG maintained its Buy rating but lowered its price target.
• For the latest quarter, Tactile Systems reported adjusted EPS of $0.31, beating estimates, while revenue of $91.86 million narrowly missed expectations. Lymphedema product revenue increased 13% year over year to $81.8 million.

Tactile Systems Technology, Inc. (NASDAQ:TCMD - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday after Wall Street Zen upgraded the stock from a buy rating to a strong-buy rating. The stock has a 200-day moving average of $25.86 and traded as high as $28.71. Tactile Systems Technology shares last traded at $27.18, with a volume of 861,535 shares traded.

Several other research firms also recently commented on TCMD. Weiss Ratings raised shares of Tactile Systems Technology from a "hold (c)" rating to a "hold (c+)" rating in a research note on Tuesday, October 13th. BTIG Research decreased their price objective on Tactile Systems Technology from $39.00 to $35.00 and set a "buy" rating for the company in a research note on Monday, October 12th. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Tactile Systems Technology has a consensus rating of "Moderate Buy" and an average target price of $36.80.

Insiders Place Their Bets

In other Tactile Systems Technology news, CEO Sheri Dodd sold 10,978 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $29.44, for a total transaction of $323,192.32. Following the completion of the transaction, the chief executive officer directly owned 232,907 shares of the company's stock, valued at approximately $6,856,782.08. This trade represents a 4.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 2.10% of the company's stock.

Tactile Systems Technology News Roundup

Here are the key news stories impacting Tactile Systems Technology this week:

• Positive Sentiment: TCMD reported Q3 adjusted earnings of $0.31 per share, above estimates of about $0.30. Lymphedema product revenue rose 13% year over year to $81.8 million, and technology improvements cut medical-record review times by about 50%. Tactile Systems: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: The stock moved above its 20-day moving average, which the article describes as a short-term bullish signal. The article also cites positive earnings-estimate revisions as a possible support for the shares. TCMD Just Overtook the 20-Day Moving Average
• Neutral Sentiment: Fiscal 2026 revenue guidance of $360 million to $366 million broadly brackets the $362.5 million consensus estimate. BTIG kept its Buy rating but cut its price target from $35 to $31, tempering the otherwise optimistic analyst outlook.
• Negative Sentiment: Quarterly revenue of $91.86 million slightly missed estimates, while earnings were down from $0.36 per share a year earlier. A report also highlighted a deepening AffloVest inventory issue, a potential offset to lymphedema growth. Tactile Medical earnings and inventory report

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TCMD. Allspring Global Investments Holdings LLC lifted its position in shares of Tactile Systems Technology by 4.1% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 19,071 shares of the company's stock valued at $425,000 after buying an additional 749 shares in the last quarter. State of Wyoming raised its position in shares of Tactile Systems Technology by 68.1% in the third quarter. State of Wyoming now owns 18,941 shares of the company's stock valued at $422,000 after buying an additional 7,670 shares during the last quarter. Inspire Investing LLC purchased a new position in shares of Tactile Systems Technology in the third quarter worth about $2,456,000. Pinnacle Associates Ltd. lifted its stake in shares of Tactile Systems Technology by 0.3% in the third quarter. Pinnacle Associates Ltd. now owns 327,967 shares of the company's stock worth $7,310,000 after buying an additional 850 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its stake in shares of Tactile Systems Technology by 18.9% in the third quarter. State of Alaska Department of Revenue now owns 7,113 shares of the company's stock worth $158,000 after buying an additional 1,132 shares in the last quarter. Institutional investors and hedge funds own 83.43% of the company's stock.

Tactile Systems Technology Stock Up 9.7%

The stock has a market capitalization of $608.83 million, a price-to-earnings ratio of 26.39 and a beta of 0.95. The business's 50-day moving average is $22.82 and its two-hundred day moving average is $25.86.

Tactile Systems Technology (NASDAQ:TCMD - Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.03. Tactile Systems Technology had a net margin of 6.68% and a return on equity of 10.73%. The company had revenue of $91.86 million during the quarter, compared to analysts' expectations of $91.99 million. As a group, analysts forecast that Tactile Systems Technology, Inc. will post 1.10 EPS for the current fiscal year.

Tactile Systems Technology Company Profile

Tactile Systems Technology, doing business as Tactile Medical, develops and provides medical devices and services for people with chronic swelling and related conditions. The company focuses primarily on lymphedema and chronic venous insufficiency, conditions that can cause persistent fluid buildup in the limbs and trunk.

Its principal products include advanced pneumatic compression devices, such as the Flexitouch Plus system for the treatment of lymphedema and the Entre Plus system for home treatment of lymphedema and chronic venous insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.